

Title Page

Quality Assessment Criteria: Psychometric properties of measurement tools for Cancer Related Fatigue

Authors

| No | Author | Credentials | Titles | Author affiliations |
|----|-------------------------------------|---------------------------------------|---|--|
| 1 | Mohammed Al Maqbali | RN., Dip. Admin., B.Sc. (Hons), M.Sc. | PhD Student | Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK |
| 2 | Ciara Hughes | PhD | Senior Lecturer, School of Health Sciences | Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK |
| 3 | Jackie Gracey (Corresponded Author) | PhD, BSc (Hons) Physiotherapy | Lecturer, School of Health Sciences | Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK |
| 4 | Jane Rankin | B.Sc. (Hons), M.Sc. | Physiotherapy Clinical Lead | Physiotherapy Department, Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK |
| 5 | Lynn Dunwoody | PhD, AFBPsS, C.Psychol, FHEA | Lecturer in Health Psychology | Psychology Research Institute, Ulster University, Coleraine, UK |
| 6 | Eileen Hacker | PhD, APN, AOCN, FAAN | Professor and Department Chair, Science of Nursing Care, Indiana University School of Nursing, and Visiting Professor, Ulster University. | School of Nursing, Indiana University, USA |

Corresponding Author:

Jackie Gracey, PhD
Shore Road, Jordanstown Campus
BT37 0QB Newtownabbey
United Kingdom
Phone+442890368284
E-mail: jh.gracey@ulster.ac.uk

Running Title: Quality Assessment Criteria for CRF Scales

| | |
|----------------------|------|
| Text word count | 5080 |
| Tables | 2 |
| Supplementary Tables | 4 |
| Figure | 1 |
| References | 111 |

Disclosures and Acknowledgement:

This review was conducted as part of PhD thesis, which was funded by the Ulster University. The authors declare no conflict of interests.

Abstract

Background: Fatigue is a common and distressing cancer symptom that negatively affects the quality of life. Many scales have been developed to assess cancer-related fatigue. The properties of the scales vary in terms of dimensionality, reliability, validity, length, and method of administration. Insufficient of psychometric properties may affect the accuracy of scales findings, that may lead result obtained questionable. The main objective of this review was to conduct a quality assessment of the psychometric properties of cancer-related fatigue scales to identify appropriate scales that could be used in research and clinical practice.

Method: A systematic search was carried out to identify validated scales that measure cancer-related fatigue. Five databases were searched: CINAHL, MEDLINE, EMBASE, PsycINFO, Cochrane Library. This review was conducted following the PRISMA and Terwee et al.'s quality assessment guidelines to evaluate the psychometric properties of the studies.

Result: Seventy-one different studies published between 1970 and 2018 met the inclusion criteria. Twenty-five scales were identified. Of these, eighteen were multidimensional and seven were uni-dimensional, containing between 4 and 72 items. Reliability and/or validity information was missing for many scales. Four scales met the quality assessment criteria and were reported as the most appropriate for measuring fatigue in cancer patients.

Conclusion: Further psychometric testing is required for other scales. Developing a universally-defined tool kit for the assessment of cancer-related fatigue may help clarify the concept of fatigue and promote a systematic approach to fatigue measurement.

Key words: Review, Cancer-Related Fatigue, Scales, Validity, Reliability.

Introduction

A cancer diagnosis is a major life stressor that affects an individual's physiological and psychological state. Patients may experience symptoms related to their cancer and/or cancer treatment with fatigue being a common and distressing symptom. Estimated prevalence rates range from 50% and 90% [1]. The variation in prevalence among similar cancer patient populations may be partially dependent upon how Cancer-Related Fatigue (CRF) is measured. Many cancer patients described fatigue highly distressing symptom affecting their quality of life [2,3]. Fatigue occurs during cancer diagnosis, treatment and throughout the survival trajectory [4] including long-term disease-free survivors [5], and advanced cancer patients [1]. CRF typically increases during radiation [6], chemotherapy [7], and biological therapy [8].

Despite the prevalence of CRF, there is no universally agreed upon definition of CRF or gold standard questionnaire to measure this troubling symptom [9]. One of the most commonly cited definitions, proposed by the National Comprehensive Cancer Network (NCCN), states that fatigue is 'a distressing persistent subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity that interferes with usual functioning' [10]. The European Association for Palliative Care (EAPC) defined CRF as a 'subjective feeling of tiredness, weakness or lack of energy' [11]. Both definitions described CRF as subjective, indicating that the assessment of fatigue should be solicited directly from the individual. One difference between the EAPC and NCCN definitions is the impact of CRF on functioning, with the latter being more comprehensive to include the consequences of fatigue on function. The conceptual definition of CRF should guide the operationalization of outcome measures used in research studies. Consequently, the different CRF definitions employed within research studies may help explain the variety of scales used to measure fatigue.

Researchers strive to use CRF scales with acceptable reliability and validity. Insufficient reporting or testing of psychometric properties may affect the accuracy of findings, leading to questionable study results [12–14]. The use of valid and reliable scales to measure CRF may lead to

improvement in patient care and development of fatigue guidelines. Four previous systematic reviews have been published which explore the reliability and validity of CRF measuring scales [15–18]. Whilst such reviews were helpful, they did not employ any structured quality assessment criteria to determine the psychometric properties of the scales being reviewed. Terwee et al. [19] provided researchers with quality assessment criteria to evaluate studies that have reported the psychometric properties of questionnaires. Hence, the purpose of this review is to assess the psychometric properties of CRF scales using the Terwee et al.'s quality assessment criteria.

Methods

Search Strategy

A systematic literature search was conducted using the following electronic databases: CINAHL, MEDLINE, EMBASE, PsycINFO, Cochrane Library, for the period from 1946 to December 2018. The search strategy used in each database was as follows: (MH "Patient Assessment+") OR (MH "Clinical Assessment Tools+") OR (MH "Functional Assessment+") OR (MH "Outcome Assessment"); (MH "Outcome Assessment") OR (MH "Measurement Issues and Assessments+"); (MH "Inventories"); (MH "Scales"); (MH "Cancer Fatigue") OR (MH "Fatigue Syndrome, Chronic"); (fatigue adj (scale or inventory or instrument or measurement or assessment)).mp.; (MH "Process Assessment (Health Care) +"); (MH "Clinical Assessment Tools+"); (MH "Measurement Issues and Assessments+") OR (MH "Psychometrics"); (MH "Fatigue+"); (MH "Hematologic Neoplasms+"); (MH "Palliative Care"); Neoplasm*; (MH "Cancer Fatigue") OR (MH "Neoplasms+"). Footnote chasing was used to identify any further studies [20].

Selection Criteria

Studies published in English with a stated study purpose to evaluate the psychometric properties of a CRF instrument were eligible for inclusion. People with cancer were the population of interest. Studies were included in the review if study participants met the following inclusion criteria: 1) aged 18 or more; 2) diagnosed with any type of cancer; 3) any stage of cancer; 4) in the case of mixed patient populations, studies were included if more than half of the participants were

diagnosed with cancer. Exclusion criteria were protocol papers and conference abstracts; single-item scales such as visual analogue scales (VAS) and fatigue subscales that were part of quality of life scales.

Assessment of measurement properties of CRF Scales:

Upon retrieval of applicable studies, CRF scales were evaluated to determine dimensionality, (unidimensional that produces one overall fatigue score versus multidimensional that produces subscales score with or without an overall fatigue score), number of items, and method of administration. The psychometric properties of CRF scales of studies included in the review were assessed using Terwee et al.'s [19] quality assessment criteria ([Supplementary Table S1](#)). These criteria specifically address eight measurement properties: content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor and ceiling effects, and interpretability. Using the descriptors provided by Terwee et al. [19], the eight criteria were applied to each CRF scales within the review and rated as positive (+); indeterminate (?); negative (-); or '0', no information available.

For ease of interpretation, this review is reported in two sections. Section One addresses Terwee et al.'s [19] quality assessment criteria to evaluate each study's report of the CRF scales. Section Two reviewed the scales' characteristics, such as the number of items, dimensions of fatigue, scoring system, administration time, the reporting period for the fatigue assessed, and the quality assessment of the scales. Unidimensional and multidimensional scales are presented separately.

Findings

The search strategy identified 2546 studies, which were screened by abstract and title. Based on the inclusion/exclusion criteria, 71 studies employing 25 different scales were included in the review (Figure 1). There were 7 unidimensional and 18 multidimensional scales; the former produced an overall fatigue score, whereas the multidimensional scales produced subscale scores and an overall CRF score.

The review evaluated 71 studies with five studies reporting more than one scale: four studies evaluated two scales [21–24] and one study evaluated three scales [25]. Each scale in each study was evaluated separately. To account for studies that evaluated multiple CRF scales, the denominator for reporting percentages was 77 studies rather than 71 (66 studies reporting the psychometric properties of one CRF scales, 4 studies reporting two scales, and one study reporting three scales).

Seventy-one psychometric studies involving 17,794 mixed cancer patients were included in this review (See [table 1 for a general characteristic of the studies](#)). The sample size ranged from 120 to 800. Study participants were diagnosed with a variety of cancers. The vast majority (n = 60 studies) included those with mixed cancer diagnoses. The remaining studies included women with breast cancer, Hodgkin's lymphoma, prostate, head and neck, and lung cancers. Nineteen different definitions of CRF were identified across the studies however only 32 studies (41.5%) included a definition of CRF. The remaining studies stated that there was no universal definition of CRF. A summary of all definitions used in the studies is presented in [Supplementary Table S 2](#).

Section One: Overall Reporting of Quality Assessment Criteria of CRF Scales

Psychometric properties were assessed for each CRF instrument based on the Terwee et al. [19], checklist (see [Table 2](#) for a summary of the evaluation). Seventy studies (91%) received a positive rating in terms of *content validity*; six (7.8 %) were indeterminate. Only one study [26] provided no information about content validity. *Internal consistency* was reported in 71 studies (92%); 68 received a positive rating (88%) and three had an indeterminate rating (4%) [27–29]. Sixty-two studies received a positive score (80.5%) for *construct validity*, while eight received an indeterminate score (10%) [30–37]. However, six studies provided no information on internal consistency [26,38–42] and one study received a negative rating in terms of *construct validity* [38] .

Studies evaluated other criterion less frequently. Only 23 studies (29.8%) provided information about *criterion validity*. Of these, 16 studies demonstrated positive (21%) criterion validity [21,27,33,38,42–52] and just seven (9%) received an indeterminate rating [37,53–58]. The remaining 54 (70%) studies did not provide information related to criterion validity. *Agreement* was

only assessed in two studies (2.5%) [26,59], which indicated a positive score for the instrument to detect minimally important changes in CRF. *Reliability* data was reported as being acceptable (i.e., at least 0.07) in 26 (34%) studies. Four studies produced an indeterminate rating (5%), and 47 (61%) studies did not provide any information. *Responsiveness* was evaluated in five studies (6.5%). One (1.3%) study received a positive rating for responsiveness [29], while four studies (5.2%) were rated as indeterminate [22,60,61]. *Floor and ceiling effects* were reported in five studies (6.5%); four receiving positive ratings (5.2%) [23][23],[62,63] and one (1.3%) an indeterminate rating [32]. Three studies (3.9%) reported *interpretation*. Two (2.6%) received an indeterminate rating [32,64] and one (1.3%) a positive rating [65].

Section Two: Scale Characteristics

The review found seven different unidimensional scales to assess CRF ([Supplementary Table S3](#)).

Unidimensional Scales: Twenty-six studies examined the psychometric properties of unidimensional scales: (a) ten explored the Brief Fatigue Inventory (BFI) scale; (b) eight used the Functional Assessment of Chronic Therapy-Fatigue subscale (FACT-F); (c) three studies assessed the Fatigue Severity Scale (FSS) scales; (d) two studies evaluated the Modified Brief Fatigue Inventory (MBFI); and (e) one study measured Four-Items Fatigue Scale (FIFS), Fatigue Assessment Scale (FAS) and Fatigue Items Bank (FIB).

The *BFI* is a measure of fatigue severity for cancer populations [53]. It consists of 9 items using a 11-point numerical rating scale. The original version was published in English. The reliability and validity were established in oncology outpatients, inpatients and healthy populations. The internal consistency (0.96) supports the reliability of the tool [53]. The BFI is quick and easy for participants to complete. This inventory has been translated into a range of languages, including Italian [43], Greek [33], German [44], Taiwan-Chinese [64], Chinese [66], Japanese [45], Korean [37], Indonesian [67] and Filipino [39]. The internal consistency in all translated versions of the BFI was high (between 0.96 to 0.91) and all versions were validated for use in mixed cancer populations. The method of translation from the original version of BFI to other languages was done according to the forward-

backward procedures. In people with cancer, the BFI meets the quality assessment criteria for content, criterion, and construct validity along with internal consistency and interpretation. Further work is needed with regard to agreement, responsiveness and floor and ceiling effects.

The scoring system of the BFI was modified (MBFI) from the original 0-10 point numeric scale to a 1-7 point scale [68]. The same 9 items were retained and validated in patients with head and neck cancer [19]. Two validation studies of the MBFI, showed good internal consistency of the subscales (coefficient alpha 0.93-0.86)[21,68]. In people with cancer, the MBFI meets the quality assessment criteria for content, criterion, and construct validity along with reliability and internal consistency. However, agreement, responsiveness, floor and ceiling effects and interpretation has not been reported.

The 9 items of BFI were reduced to 4 to develop the FIFS [38]. It was tested in patients with different types of cancer. The FIFS did not predict fatigue over time and the reliability of the scale needs to be confirmed in further studies. In people with cancer, the FIFS meets the quality assessment criteria for content and criterion validity. Reliability, internal consistency agreement, responsiveness, floor and ceiling effects and interpretation have yet to be reported.

The *FACT-F* is a 13-item questionnaire using a 5-point Likert scale to assess fatigue [46]. It has been validated for use with a variety of cancer diagnoses and treatments [46]. The original *FACT-F* showed strong internal consistency (*coefficient alpha* 0.93-0.95) and good stability (*test-retest, r* =0.87) [46]. The *FACT-F* has been translated in to 57 languages using iterative forward-backward translation methodology [69]. Eden and Kunkel [21] validated the *FACT-F* with patients with head and neck cancer and reported good internal consistency (Cronbach's alpha 0.87) and test-retest reliability (*r*=0.95). Other psychometric studies using the instrument translated it into Spanish [61], French and Dutch [70], Japanese [40], Persian [71], and Portuguese [26,72]. Internal consistency of the translated scales ranged from between 0.79 to 0.94. In people with cancer, the *FACT-F* meets the quality assessment criteria for content, criterion, and construct validity along with agreement,

reliability and internal consistency. Further work, however, is needed on responsiveness, floor and ceiling effects, and interpretation.

The *FAS* includes 10-items and uses a 5-point Likert scale to assess physical and mental fatigue. Even though the *FAS* assesses two dimensions of fatigue, it is categorized as unidimensional as only the overall fatigue score should be used [73,74]. De Vries et al. [75] assessed the psychometric properties in a working population of 560 Dutch breast cancer patients; the results showed good internal consistency (Cronbach's alpha 0.89) and test-retest reliability ($r=0.88$). The *FAS* meets the quality assessment criteria for content and construct validity along with internal consistency and reliability. Further work is needed on criterion validity, agreement, responsiveness, floor and ceiling effects and interpretation.

The *FSS* includes 9 items and uses a 7-point Likert scale. The *FSS* was originally validated in multiple sclerosis and systemic lupus erythematosus populations [76]. The psychometric properties were assessed in advanced cancer patients [54] and mixed cancer patients [28]. The coefficient alpha of the two studies ranged from 0.94 to 0.96. Based on the review findings, the *FSS* meets the quality assessment criteria for content, criterion, and construct validity along with reliability, internal consistency and interpretation. Agreement, responsiveness and floor and ceiling effects have not been reported.

The *FIB* is a 72-item, 5-point Likert scale which was developed to measure CRF in a computerized adaptive testing format [63]. The scale was validated in 301 mixed cancer patients. The *FIB* shows good psychometric properties using Rasch analysis. The internal consistency was 0.99 and item total correlation was between 0.51 and 0.85. The factor analysis conformed that 72 items were unidimensional. The authors provided a 6-item short form *FIB* for use in a clinical setting. In people with cancer, the *FIB*-72 items met the quality assessment criteria for content and construct validity, floor and ceiling effects along with internal consistency. Further work is needed on criterion validity, agreement, reliability, interpretation and responsiveness.

Multidimensional Scales: The review found 50 studies that investigated the properties of 18 multidimensional scales of fatigue. All 18 multidimensional scales provided an overall fatigue score, as well as subscale scores to represent specific domains of fatigue (Supplementary Table S 4 for more details).

The *Multidimensional Fatigue Inventory (MFI)* is a 20-item, 5-point Likert scale designed to measure general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity [77]. The scale was originally validated in Dutch cancer patients, non-cancer chronic fatigue syndrome patients, army recruits and medical students [77]. Smets et al. [78] validated the MFI-20 in a Dutch and Scottish patients with cancer and reported good internal consistency (coefficient alpha 0.79 to 0.93). The MFI-20 has been translated into several languages; French [56], Chinese [57], Brazilian Portuguese [79], Polish [55], Hindi [80], and Swedish [81], utilising the back-translation process. Overall, internal consistency was acceptable in all translated versions of the MFI (between 0.80 to 0.90). In people with cancer, the MFI-20 meets the quality assessment criteria for content, criterion, and construct validity along with internal consistency and interpretation. Further work is needed on test-retested reliability, agreement, responsiveness and floor and ceiling effects.

The *Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)* is a 30-item, 5-point Likert scale that was designed specifically for use with breast cancer patients [82]. There are 5 subscales; physical, emotional, mental, vigour and general fatigue. Initial psychometric testing occurred in 224 breast cancer patients, who were undergoing chemotherapy and radiotherapy, and the scale demonstrated very good validity and reliability [82]. Additional psychometric studies were conducted in English [83], Chinese[84] and Singapore Chinese [60] and the internal consistency of the subscales ranged from 0.74 to 0.96. In people with cancer, the MFSI-SF met the quality assessment criteria for content and construct validity along with internal consistency, reliability and responsiveness. Criterion validity, agreement, floor and ceiling effects and interpretation were not reported.

Schwartz [85] published the first version of the *Schwartz Cancer Fatigue Scale (SCFS)*, which has 28-items using a 5-point Likert scale. The *SCFS* assess four fatigue dimensions; physical, cognitive, temporal and emotional and was specifically designed to measure CRF. The coefficient alpha for total scale score was 0.96, and subscales ranged from 0.82 to 0.93. A revised version, the *SCFS-6* contains only 6-items, measuring the physical and perceptual dimensions of CRF and has shown good internal consistency (coefficient alpha 0.81 to 0.88) [86] and 0.85 [29]. The *SCFS-6* was translated into Chinese and had good internal consistency (coefficient alpha 0.88 to 0.89) [23,25] using backward transitional methods. In people with cancer, the *SCFS-6* met the quality assessment criteria for content and construct validity along with reliability, internal consistency, floor and ceiling effects and responsiveness. Further work is needed on criterion validity, agreement, and interpretation.

The Fatigue Symptom Inventory (FSI) consists of 13 items that assess the intensity, duration, daily pattern and interference of fatigue [87]. The *FSI* was originally developed using a sample of patients with breast cancer, both during and after treatment. The internal consistency of the subscales had a coefficient alpha above 0.90 in all groups. Hann et al. [88] tested *FSI* in a mixed cancer population and found an overall coefficient alpha of 0.94. The *FSI* was translated into Chinese and had a Cronbach's alpha score of between 0.70 to 0.90 [23,25]. In people with cancer, the *FSI* met the quality assessment criteria for content, criteria and construct validity as well as reliability, internal consistency and floor and ceiling effects. Agreement, responsiveness and interpretation have not been assessed.

The original *Piper Fatigue Scale* consisted of 40 items [89]; reduced to 22 items in the revised version (*PFS-R*) [34]. The revised version measured four subscales: behavioural/severity, affective meaning, sensory and cognitive/mood. The scales were validated in 382 breast cancer survivors. Internal consistency was high, over 0.90. The *PFS-R* has been validated in eight languages. Two psychometric studies were conducted in Italian [30,48]. Other validation studies were performed in Spanish [41], Swedish [27,90], Dutch [47], Portuguese [91], Chinese [35] and Korean [31]. All translated versions of the *PFS-R* showed good internal consistency. A further reduction in the *PFS*

items was carried out to create a 12-item scale (PFS-12) [92], with the reliability of the item subscales being between 0.87 and 0.98. The PFS-12 measured four subscales: behavioural, affective, sensory, and cognitive/mood. In people with cancer, the PFS-R met the quality assessment criteria for content, construct, and criterion validity along with reliability and internal consistency. Further work is needed on agreement, responsiveness, floor and ceiling effects and interpretation.

The *Perform Questionnaire* (PQ) [62] consists of 12 items and was originally developed to measure fatigue among Spanish-speaking cancer patients. The scale assesses three dimensions: physical limitations, activities of daily living, and beliefs and attitudes. The scale was validated with a 238 mixed cancer patient population receiving adjuvant treatment, curative treatment, and palliative care. The internal consistency ranged from 0.78 to 0.92. Another psychometric study conducted by Baró et al.[65] found an overall internal consistency of 0.94 and test-retest reliability of 0.83. The PQ had good validity and reliability but was only validated in Spanish. In people with cancer, the PQ meets the quality assessment criteria for content, and construct validity along with reliability, internal consistency, interpretation and floor and ceiling effects. Further work is needed on criterion validity, agreement and responsiveness.

The *Lee Fatigue Scales* (LFS) is an 18-item scale, which was originally developed to measure fatigue in patients with sleep disorders and is also known as the Visual Analogue Scale for Fatigue, (VASF) [93]. The LFS has two subscales: fatigue (13 items) and energy (5 Items). The psychometric properties in cancer patients were assessed by Meek et al. [22]. The scale demonstrated good reliability but low stability because of sensitivity to morning and evening changes [22]. Lerdal et al. [32] evaluated the psychometric properties of the 13 fatigue item subscale of the LFS in 587 mixed cancer patients. Pearson's correlation coefficients of the LFS were deemed acceptable (*test-retest* $r = 0.88$). In people with cancer, the LFS 13-items met the quality assessment criteria for content and construct validity along with internal consistency and responsiveness. Further work is needed on criterion validity, agreement, reliability, floor and ceiling effects and interpretation.

The *Multidimensional Assessment of Fatigue (MAF)* consists of 16 items scored on a scale ranging from 0 to 10 and originally validated in rheumatoid arthritis patients [94]. The MAF has four dimensions of fatigue; severity, distress, and degree of interference in activity of daily living, and timing. Winstead-Fry [24], tested the MAF in a mixed cancer patient population and found adequate internal consistency. Additional psychometric testing was carried out in a cancer population by Meek et al. [22] who reported the overall coefficient alpha to be 0.88. Despite this, the MAF failed to show adequate construct validity in terms of a four factor structure [22]. Several studies did not recommend using MAF unless further validation has been performed in the cancer population [15,17]. In people with cancer, the MAF met the quality assessment criteria for content validity as well as internal consistency. Further testing of criterion and construct validity, reliability, agreement, responsiveness, floor and ceiling effects and interpretation is required.

The *Cancer Fatigue Scale (CFS)* is a 15-item, 5-point Likert scale composed of three domains: physical, affective and cognitive [58]. It was validated in Japanese cancer patients. The reliability coefficients ranged from between 0.84 and 0.88. The construct validity showed a good score for the instrument (0.32 - 0.67). Okuyama et al. [95] tested the CFS in breast cancer patients and found Cronbach's alpha coefficients ranged from 0.76 to 0.89. Validation was completed for the Japanese version only. The CFS was translated into English but not tested psychometrically. Other translations include Chinese [25], Dutch [96], Turkish [52] and Greek [49] with good reliability (0.74 to 0.91). Based on the review findings, the CFS met the quality assessment criteria for content, construct, and criterion validity as well as internal consistency. Further work is needed on agreement, interpretation, floor and ceiling effects and responsiveness.

The *Hirai Cancer Fatigue Scale (HCFS)* is a 15-item, 5-point Likert scale, with three subscales; physical, mental, and cognitive fatigue [50]. The psychometric properties were assessed in a mixed cancer population of 281 patients undergoing treatment. The overall Cronbach's alpha coefficient was 0.94, supporting internal consistency and a test-retest reliability coefficient of 0.82. The HCFS had high reliability and high validity based on the Japanese cancer population, but further

validation is needed for the English version. In people with cancer, the HCFS met the quality assessment criteria for content, criterion, and, construct validity as well as internal consistency and reliability in a Japanese population. Further work is needed on agreement, responsiveness floor and ceiling effects and interpretation.

The *Cancer-Related Fatigue Distress Scale (CRFDS)* is a 20-item scale that was originally investigated in a heterogenous cancer population [59]. The scale used an 11-point numerical rating scale to assess five domains; physical, social, psychological, cognitive, and spiritual fatigue. The scale has very good validity and reliability. The internal consistency reliability was 0.98. In people with cancer, the CRFDS met the quality assessment criteria for content and construct validity as well as internal consistency. The criterion validity, reliability, responsiveness, floor and ceiling effects and interpretation were not reported.

The *Swedish Occupational Fatigue Inventory (SOFI)* is a 25-item scale that was originally validated in work-related fatigue studies [36]. The scale measures five fatigue domains; lack of energy, physical exertion, physical discomfort, lack of motivation, and sleepiness. The SOFI was validated in a mixed Swedish cancer population of 81 patients receiving radiotherapy. The SOFI met the quality assessment criteria for content and criterion as well as internal consistency, interpretation, and floor and ceiling effects. Further work is needed on criterion and construct validity, reliability, agreement, responsiveness, floor and ceiling effects and interpretation. Further psychometric analyses are required with a larger sample size.

The *Wu Cancer Fatigue Scale (WCFS)* has two versions. The original consists of 16 items with a 5-point Likert scale designed to assess physical, emotional, and cognitive fatigue [42]. It was tested in women with breast cancer undergoing chemotherapy. The scale shows adequate reliability and criterion-related validity. The three-factor model was not supported by exploratory factor analysis. The items in the revised WCFS-9 were reduced to 9 items [51]. In people with cancer, the WCFS-9 meets the quality assessment criteria for content, criterion, and construct validity along with

internal consistency. Further work is needed on agreement, reliability, responsiveness and floor and ceiling effects and interpretation.

The Fatigue Functional Impact Scale (FFIS) was constructed to assess fatigue and functional impairment in an 8-item, 10-point Likert scale [97]. The psychometric properties were assessed in 1355 mixed cancer patients receiving chemotherapy. The FFIS showed strong internal consistency with coefficient alpha scores of 0.90. In people with cancer, the FFIS met the quality assessment criteria for content and construct validity along with internal consistency. Criterion validity, agreement, reliability, floor and ceiling effects, interpretation and responsiveness were not assessed.

The General Fatigue Scale (GFS) is a 7-item scale that assesses overall fatigue intensity, distress level and disruptions of daily activity, and was designed to use for randomised controlled trials to measure fatigue at specific time-points [98]. The scale was validated and translated into Chinese [98]; the Cronbach's alpha reliability coefficient was 0.94. In people with cancer, the GFS met the quality assessment criteria for content validity, construct validity, internal consistency and reliability. Criterion validity, agreement, floor and ceiling effects, responsiveness and interpretation were not reported.

Discussion

Assessing the impact of fatigue on people with cancer is imperative for understanding this distressing symptom and necessary for determining the impact of interventions on CRF. This review is the first to perform a quality assessment of CRF scales employing Terwee's criteria of content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor and ceiling effects, and interpretability [19]. Twenty-five scales assessed fatigue in adult cancer patients, considerably more than earlier reviews [15,17,18,99]. The quality assessment of CRF indicated that content, criterion, and construct validity along with internal consistency were the most frequently met criteria, demonstrating that the vast majority of scales undergo at least some psychometric testing of validity and internal consistency reliability. On the other hand, reproducibility, in the form of agreement and intraclass correlation reliability, responsiveness, floor

and ceiling effects, and interpretability are generally not assessed and/or reported as part of the psychometric testing. No study explored all of the Terwee et al. [19] quality assessment criteria in evaluating the psychometric properties of CRF scales.

The use of Terwee et al.'s [19] guidelines for assessing the psychometric properties of CRF scales allows users to distinguish between and make a judgment about the most appropriate choice of CRF scale. While each individual quality assessment criterion is important, the Terwee assessment does not result in an overall psychometric rating of a scale; thus, avoiding the assumption that all of the quality assessment criteria are equal. Terwee et al. [19] suggested that the most important criteria of the nine measurement properties was content validity, as absence of content validity can impact all other measurement properties [100]. All of the scales in this review met the criterion for content validity; however, this indicator on its own, may not be helpful to researchers in selecting a CRF instrument.

Although other reviews of CRF scales have been conducted [15–18], this current psychometric review of CRF scales adds to the literature. This review used different search terms and inclusion criteria and the search was conducted in additional databases compared to the previous reviews [15–18]. As a result, this review included more studies by using different Medical Subject Headings (MeSH) terms and databases. This review evaluated scales using the Terwee et al.[19] checklist for critical evaluation of psychometric properties for each of the studies that evaluated CRF scales. Hence, the current review adds new evidence by presenting each scale for CRF using well-defined criteria of psychometric properties. The most comprehensively validated scales were the BFI, FACT-F, MFI-20 and PFS-R. These received positive ratings in content validity, internal consistency, criterion validity, construct validity and reliability. In addition, these scales have been translated and psychometrically tested in different languages; adding to their value for use in people with cancer.

There are several other factors that need to be taken into consideration by researchers and clinicians when choosing a CRF scale. There is a need to clearly understand the phenomenon of CRF. Unfortunately, the lack of a consensus definition has led to the development of multiple scales

assessing various dimensions or domains of CRF phenomena [9]. It is imperative that the conceptual definition of fatigue is logically consistent with operationalization of the concept. The CRF scales assessed within this review have different foci (e.g., some addressed fatigue severity while others assessed impact on function). The focus of the CRF instrument should be consistent with the research question. In addition, the heterogeneity of the type, the stage of cancer, treatment, and type of management may entail different fatigue experiences, in terms of precedence and severity; thus, selection of a CRF scale should consider these factors. For example, the population in which the scale was validated previously should be taken into consideration, as cultural contexts and beliefs may impact on suitability or applicability of scale items.

There are few limitations to this review. Although this review included 71 studies using different Medical Subject Headings (MeSH) terms and databases, it is possible that some psychometrics studies were not included. This review was restricted to studies published in English. Other psychometric studies evaluating CRF scales published in a language other than English were not included in this review.

Conclusion

This review identified seven scales that produce an overall fatigue score and eighteen scales that produce fatigue subscale score with or without an overall fatigue scale score. These scales were drawn from 77 studies assessing fatigue in people with cancer. This paper is the first to conduct a quality assessment of scales used to measure CRF in people with cancer. Four scales meeting the most quality assessment criteria, within a cancer population, two unidimensional (BFI and FACT-F) and two multidimensional (MFI-20 and PFS- R). Consideration should be given when choosing an appropriate scale for research or clinical propose, as each scale measures different dimensions or aspects of CRF. The least likely criteria to be assessed included test-retest reliability, agreement, responsiveness, interpretation, and floor and ceiling effects. Given the importance of linking conceptual and operationalization of fatigue in people with cancer, recommendations to move

forward with a universally accepted definition of fatigue would further help to advance healthcare science and clinical practice.

Table 1: The assessment of measurement properties of CRF scale (N=77):

| Scale | | | | | Reproducibility | | | | |
|---|------------------|----------------------|--------------------|--------------------|-----------------|-------------|----------------|---------------------------|----------------|
| | Content Validity | Internal Consistency | Criterion Validity | Construct Validity | Agreement | Reliability | Responsiveness | Floor and Ceiling Effects | Interpretation |
| 1 Brief Fatigue Inventory (BFI) Mendoza et al., [53] | + | + | ? | + | 0 | 0 | 0 | 0 | 0 |
| 2 BFI-Italian, Catania et al., [43] | + | + | + | + | 0 | 0 | 0 | 0 | 0 |
| 3 BFI-Greek, Meztekde et al., [33] | + | + | + | ? | 0 | + | 0 | 0 | 0 |
| 4 BFI-German Radbruch et al. [44] | + | + | + | + | 0 | + | 0 | 0 | 0 |
| 5 BFI-Taiwanese, Lin et al., [64] | + | + | 0 | + | 0 | + | 0 | 0 | ? |
| 6 BFI-Chinese, Wang et al. [66] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 7 BFI-Japanese, Okuyama [45] | + | + | + | + | 0 | 0 | 0 | 0 | 0 |
| 8 BFI-Korean, Yun et al., [37] | + | + | ? | ? | 0 | 0 | 0 | 0 | 0 |
| 9 BFI-Indonesian, Paramita et al [67] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 10 BFI-Filipino, Mendoza et al., [39] | + | 0 | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 11 MBFI, Aynehchi et al., [68] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 12 MBFI, Eden & Kunkel, [21] | + | + | + | 0 | 0 | + | 0 | 0 | 0 |
| 13 FIFS, Davis et al., [38] | ? | 0 | + | - | 0 | 0 | 0 | 0 | 0 |
| 14 FACT-F, Yellen, et al, [46] | + | + | + | 0 | 0 | + | 0 | 0 | 0 |
| 15 FACT-F, Spanish, Dapuerto, et al, [61] | + | + | 0 | + | 0 | + | ? | 0 | 0 |
| 16 FACT-F, French and Dutch, Van Belle et al., [70] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 17 FACT-F, Portuguese, Ishikawa et al., [72] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 18 FACT-F, Portuguese, Ishikawa et al., [26] | 0 | 0 | 0 | 0 | + | + | 0 | 0 | 0 |
| 19 FACT-F, Japanese, Yoshimura et al., [40] | + | 0 | 0 | + | 0 | + | 0 | 0 | 0 |
| 20 FACT-F, Persian, Meysami, et al., [71] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 21 FACT-F, Eden & Kunkel [21] | + | + | + | 0 | 0 | + | 0 | 0 | 0 |
| 22 Fatigue Assessment Scale (FAS), De Vries et al [75] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 23 Fatigue Severity Scale FSS, Winstead-Fry P.,[24] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 24 FSS, Stone et al, [54] | ? | + | ? | + | 0 | + | 0 | 0 | 0 |
| 25 FSS, Stone et al, [28] | ? | ? | 0 | 0 | 0 | + | 0 | 0 | 0 |
| 26 Fatigue items bank (FIB) Lai et al, [63] | + | + | 0 | + | 0 | 0 | 0 | + | 0 |
| Multidimensional instrument | | | | | | | | | |
| 27 Multidimensional Fatigue Inventory (MFI-20) MFI-20-Dutch, Smets et al., [77] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 28 MFI-20 English, Smets et al. [78] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 29 MFI-20 Brazilian, Portuguese Baptista et al. [79] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 30 MFI-20 Polish, Buss et al. [55] | + | + | ? | + | 0 | 0 | 0 | 0 | 0 |
| 31 MFI-20 Swedish, Lundh et al. [81] | ? | + | 0 | + | 0 | 0 | 0 | 0 | 0 |

| | | | | | | | | | | |
|----|--|---|---|---|---|---|---|---|---|---|
| 32 | MFI-20 French, Fillion et al., [56] | + | + | ? | + | 0 | 0 | 0 | 0 | 0 |
| 33 | MFI-20 Hindi, Chandel et al. [80] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 34 | MFI-20 Chinese , Tian & Hong [57] | + | + | ? | + | 0 | 0 | 0 | 0 | 0 |
| 35 | Fatigue Symptom Inventory-Short Form Stein et al., [82] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 36 | MFSI-SF Stein et al., [83] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 37 | MFSI-SF-C Pien et al., [84] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 38 | MFSI-SF-C Chan et al., [60] | + | + | 0 | + | 0 | + | ? | 0 | 0 |
| 39 | Schwartz Cancer Fatigue Scale SCFS Schwartz,[85] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 40 | SCFS-R, Schwartz & Meek, [86] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 41 | SCFS-R Schwartz et al., [29] | + | ? | 0 | 0 | 0 | ? | + | 0 | 0 |
| 42 | SCFS-R Chinese, Shun et al. [25] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 43 | SCFS-R Chinese Shun et al. [23] | + | + | 0 | + | 0 | ? | 0 | + | 0 |
| 44 | Fatigue Symptom Inventory FSI, Hann et al [87] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 45 | FSI Hann et al [88] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 46 | FSI- Chinese, Shun, et al. [25] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 47 | FSI- Chinese, Shun, et al. [23] | + | + | 0 | + | 0 | ? | 0 | + | 0 |
| 48 | Piper Fatigue Scale-Revised (PFS-R) Piper et al. [34] | + | + | 0 | ? | 0 | ? | 0 | 0 | 0 |
| 49 | PFS-R Korean, Lee [31] | + | + | 0 | ? | 0 | + | 0 | 0 | 0 |
| 50 | PFS-R Spanish, Cantarero-Villanueva et al., [41] | + | 0 | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 51 | PFS-R Swedish, Jakobsson et al, [27] | + | + | + | + | 0 | 0 | 0 | 0 | 0 |
| 52 | PFS-R Swedish, Lundgren-Nilsson, et al., [90] | ? | ? | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 53 | PFS-R Dutch, Dagnelie et al. [47] | + | + | + | + | 0 | 0 | 0 | 0 | 0 |
| 54 | PFS-R Brazilian, Mota et al. [91] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 55 | PFS-R Italian Giacalone et al. [48] | + | + | + | + | 0 | 0 | 0 | 0 | 0 |
| 56 | PFS-R Italian, Annunziata et al. [30] | + | + | 0 | ? | 0 | 0 | 0 | 0 | 0 |
| 57 | PFS-R Chinese So et al., [35] | ? | + | 0 | ? | 0 | 0 | 0 | 0 | 0 |
| 58 | PFS-12 Reeve et al. [92] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 59 | Perform Questionnaire Baró et al., [62] | + | + | 0 | + | 0 | 0 | 0 | + | 0 |
| 60 | PQ, Baró et al., [65] | + | + | 0 | + | 0 | + | 0 | 0 | + |
| 61 | Lee Fatigue Scale (LFS) Meek et al., [22] | + | + | 0 | + | 0 | 0 | ? | 0 | 0 |
| 62 | Lee Fatigue Scale (LFS) Lerdal et al., [32] only 13-items of fatigue. | + | + | 0 | ? | 0 | + | 0 | ? | ? |
| 63 | Multidimensional Assessment of Fatigue (MAF) Meek et al. [22] | + | + | 0 | + | 0 | 0 | ? | 0 | 0 |
| 64 | MAF Winstead-Fry [24] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 65 | Cancer Fatigue Scale (CFS) Okuyama et al., [58] | + | + | ? | + | 0 | + | 0 | 0 | 0 |
| 66 | CFS -J Okuyama et al., [95] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |

| | | | | | | | | | | |
|----|---|---|---|---|---|---|---|---|---|---|
| 67 | CFS- Chinese, Shun et al., [25] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 68 | CFS- Dutch, Kröz et al., [96] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 69 | CFS- Turkish, ŞAHİN, et al., [52] | + | + | + | + | 0 | + | 0 | 0 | 0 |
| 70 | CFS- Greek Charalambous, et al., [49] | + | + | + | + | 0 | + | 0 | 0 | 0 |
| 71 | Hirai Cancer Fatigue Scale Hirai et al., [50] | + | + | + | + | 0 | + | 0 | 0 | 0 |
| 72 | Cancer-Related Fatigue Distress Scale (CRFDS) Holley [59] | + | + | 0 | + | + | 0 | 0 | 0 | 0 |
| 73 | Swedish Occupational Fatigue Inventory Åhsberg & Fürst [36] | + | + | 0 | ? | 0 | 0 | 0 | 0 | 0 |
| 74 | 16-item scale (WCFS), Wu & McSweeney, [42] | + | 0 | + | + | 0 | 0 | 0 | 0 | 0 |
| 75 | Wu Cancer Fatigue Scale (WCFS-9) Wu et al., [51] | + | + | + | + | 0 | 0 | 0 | 0 | 0 |
| 76 | Fatigue Functional Impact Scale (FFIS) Cella et al., [97] | + | + | 0 | + | 0 | 0 | 0 | 0 | 0 |
| 77 | General Fatigue Scale (GFS), Chou et al., [98] | + | + | 0 | + | 0 | + | 0 | 0 | 0 |

Table S1: Quality criteria for measurement properties of scales

| Property | Definition | Quality Criteria |
|------------------------|---|--|
| 1 Content validity | The amount to which the domain of Interest is comprehensively sampled by the items in the questionnaire | <p>+ A clear description is provided of the measurement aim, the target population, the concepts that are being measured, and the item selection AND target population and (investigators OR experts) were involved in item selection;</p> <p>? A clear description of above-mentioned aspects is missing, OR only target Population involved OR doubtful design or method;</p> <p>- No target population involvement;</p> <p>0 No information found on target population involvement.</p> |
| 2 Internal Consistency | The amount to which items in a (sub) scale Are intercorrelated, so measuring the same construct | <p>+ Factor analyses performed on adequate sample size (7 * # items and > 100) AND Cronbach's alpha (s) calculated per dimension AND Cronbach's alpha (s) Between 0.70 and 0.95;</p> <p>? No factor analysis OR doubtful design or method;</p> <p>- Cronbach's alpha (s) < 0.70 or < 0.95, despite adequate design and method;</p> <p>0 No information found on internal consistency.</p> |
| 3 Criterion validity | The extent to which scores on a Particular questionnaire refer to a gold Standard | <p>+ Convincing arguments that gold standard is " gold " AND correlation with gold standard > 0.70;</p> <p>? No convincing arguments that gold standard is " gold " OR doubtful design or Method;</p> <p>- Correlation with gold standard < 0.70, continuous adequate design and method;</p> <p>0 No information found on criterion validity.</p> |
| 4 Construct validity | The amount to which scores on a Particular questionnaire refer to other Measures in a manner that is consistent with theoretically derived hypotheses Relating the concepts that are being measured | <p>+ Specific hypotheses were formed and at least 75% of the results are in accordance with these hypotheses;</p> <p>? Doubtful design or method (eg, no hypotheses</p> <p>- Less than 75% of hypotheses were confirmed, despite adequate design and Methods;</p> <p>0 No information found on construct validation.</p> |
| 5 Reproducibility | | |
| 5.1. Agreement | The amount to which the scores on repeated measures are close to each other (absolute measurement error) | <p>+ MIC < SDC OR MIC outside the LOA OR convicting arguments that agreement is acceptable;</p> <p>? Doubtful design or method OR (MIC not defined AND no convincing arguments that agreement is acceptable</p> <p>- MIC > SDC OR MIC equals or inside LOA, despite adequate design and method;</p> <p>0 No information found on agreement.</p> |
| 5.2. Reliability | The amount to which patients can be | <p>+ ICC or weighted Kappa > 0.70;</p> <p>? Doubtful design or method (eg, time interval not mentioned);</p> |

| | | |
|---|---|--|
| | Distinguished from each other, despite Measurement errors (Relative measurement error) | <ul style="list-style-type: none"> - ICC or weighed Kappa! 0.70, despite adequate design and method; 0 No information found on reliability. |
| 6 | Responsiveness The ability of a questionnaire to detect Clinically important changes over time | <ul style="list-style-type: none"> + SDC or SDC! MIC OR MIC outside the LOA OR RRO1.96 OR AUC > 0.70; ? Doubtful design or method; - SDC or SDC > MIC OR MIC equals or inside LOA OR RR < 1.96 OR AUC! 0.70, despite adequate design and methods 0 No information found on responsiveness. |
| 7 | Floor and ceiling Effects The number of responders who achieved the lowest or highest possible score | <ul style="list-style-type: none"> + <15% of the respondents achieved the highest or lowest possible scores; ? Doubtful design or method; - >15% of the respondents achieved the highest or lowest possible scores, strict adequate design and methods; 0 No information found on interpretation. |
| 8 | Interpretability The degree to which one can assign Qualitative meaning to quantitative scores | <ul style="list-style-type: none"> + Mean and SD scores presented at least four relevant subgroups of patients and MIC defined; ? Doubtful design or method OR less than four subgroups OR no MIC defined; 0 No information found on interpretation. |

* This table adapted from Terwee et al.[19] page 39

Table S2: Characteristics of the Studies

| | Scale with references | Design | Fatigue definition | Sample | Type of cancer | <u>Time of intervention</u> | Language | Internal consistency Cronbach's Coefficient Alpha | Test & Retest Correlation coefficient |
|------------------------------|--|-----------------|---------------------------|---------------|---------------------------------------|------------------------------------|---------------------|--|--|
| Unidimensional Scales | | | | | | | | | |
| 1 | Brief Fatigue Inventory (BFI) Mendoza et al., [53] USA | Cross-sectional | Not given | 305 | Mixed Cancer Patient | Not specify | English | α 0.96 | |
| 2 | BFI-Italian, Catania et al., [43] Italy | Cross-sectional | Not given | 341 | Mixed Cancer Patient | Mixed | Italian | α 0.94 | |
| 3 | BFI-Greek, Meztekd et al., [33] Greek | Longitudinal | Not given | 102 | Mixed Cancer Patient | Mixed | Greek | α 0.95 | |
| 4 | BFI-German Radbruch et al. [44] Germany | Longitudinal | Def (2) | 117 | Mixed Cancer Patient | Not specify | German | α 0.91 | |
| 5 | BFI-Taiwanese, Lin et al., [64] Taiwan | Longitudinal | Def (1) | 439 | Mixed cancer Patients | Not specify | Chinese (Taiwanese) | α 0.96 | |
| 6 | BFI-Chinese, Wang et al. [66] China | Cross-sectional | Not given | 249 | Mixed cancer Patients | Mixed | Chinese | α 0.86 to 0.91 | |
| 7 | BFI-Japanese, Okuyama [45] Japan | Cross-sectional | Not given | 252 | Mixed cancer Patients | Mixed | Japanese | α 0.96 | |
| 8 | BFI-Korean, Yun et al., [37] Korea | Cross-sectional | Not given | 178 | Mixed cancer Patients | Not specify | Korean | α 0.95 | |
| 9 | BFI-Indonesian, Paramita et al., [67] Indonesia | Cross-sectional | Not given | 121 | Mixed cancer Patients | Not specify | Indonesian | α 0.95 | |
| 10 | BFI-Filipino, Mendoza et al., [39] Philippines | Cross-sectional | Not given | 206 | Mixed cancer Patients | Mixed | Filipino | α 0.95 | |
| 11 | MBFI, Aynehchi et al., [68] USA | Longitudinal | Not given | 52 | Head and Neck cancer | Mixed | English | α 0.938 | Test & Retest r =0.814 |
| 12 | MBFI, Eden & Kunkel, [21] USA | Longitudinal | Def 18 | 65 | Head and neck skin and thyroid cancer | Mixed | English | α 0.869 | Test & Retest r =0.865 |
| 13 | Fatigue Functional Impact Scale (FFIS), Davis et al., [38] USA | Longitudinal | Def (3) | 65 | Mixed advanced cancer Patients | Not specify | English | | |

| | | | | | | | | | |
|----|--|-----------------|-----------|-----|---------------------------------------|---------------------|------------------|---|--|
| 14 | Functional Assessment of Chronic Therapy-Fatigue (FACT- F) Yellen, et al. [46] USA | Longitudinal | Def 4 | 49 | Mixed Cancer Patient | Mixed | English | α 0.90 C. α 0.93 to 0.95 | Test & Retest $r = 0.87$ |
| 15 | FACT- F, French and Dutch Van Belle et al., [70] Belgium | Cross-sectional | Def 5 | 834 | Mixed Cancer Patient | Mixed | French and Dutch | α 0.94 | |
| 16 | FACT-F, Spanish Dapueto, et al, [61] Uruguay | Longitudinal | Def 4 | 79 | Mixed cancer patients | Mixed | Spanish | α 0.88 | |
| 17 | FACT-F, Portuguese Ishikawa et al., [72] Brazil | Longitudinal | Not given | 270 | Mixed cancer patients | Mixed | Portuguese | α 0.92 | |
| 18 | FACT-F, Portuguese Ishikawa et al., [26] Brazil | Longitudinal | Not given | 85 | Mixed cancer patients | Mixed | Portuguese | α 0.79 | Test & Retest $r = 0.85$ |
| 19 | FACT- F, Japanese Yoshimura et al., [40] Japan | Cross-sectional | Not given | 180 | Lung cancer | Not specify | Japanese | α 0.93 | Test-retest $r = 0.43-0.70$ |
| 20 | FACT-F, Persian Meysami, et al., [71] Iran | Longitudinal | Not given | 208 | Breast cancer | Completed treatment | Persian | α 0.91 | Test-retest $r = 0.91$ |
| 21 | FACT-F, Eden & Kunkel, [21] USA | Longitudinal | Def 18 | 65 | Head and neck skin and thyroid cancer | Mixed | English | α 0.911 | Test & Retest $r = 0.951$ |
| 22 | Fatigue Assessment Scale (FAS) De Vries et al [75] Netherland | Longitudinal | Not given | 204 | Breast cancer | Not specify | Dutch | α 0.88 to 0.90 | Test & Retest $r = 0.87$ and $r = 0.88$ |
| 23 | Fatigue Severity Scale (FSS) Winstead-Fry P., [24] USA | Cross-sectional | Def 17 | 131 | Mixed cancer Patients | Not specify | English | $\alpha = 0.95$ | |
| 24 | FSS, Stone et al, [54] UK | Longitudinal | Def 6 | 95 | Mixed advanced cancer Patients | Not specify | English | $\alpha = 0.94$ | Test-retest reliability Calculated by measurement error was 4.7 |
| 25 | FSS, Stone et al, [28] UK | Longitudinal | Def 7 | 227 | Mixed cancer Patients | Not specify | English | $\alpha = 0.96$ | Test-retest reliability Calculated by measurement error was 4.7 unites (satisfactory) |

| | | | | | | | | | |
|----|--|-----------------|--------|-----|-----------------------|-------------|---------|-----------------|--|
| 26 | Fatigue Items Bank (FIB) Lai et al, [63] USA | Cross-sectional | Def 11 | 301 | Mixed cancer patients | Not specify | English | $\alpha = 0.96$ | |
|----|--|-----------------|--------|-----|-----------------------|-------------|---------|-----------------|--|

Multidimensional Scales

| | | | | | | | | | |
|----|---|-----------------|-----------|--------------------------|-------------------------------------|-------------------------|----------------------|---|--|
| 27 | Multidimensional Fatigue Inventory (MFI-20) Dutch, Smets et al., [77] Netherland | Cross-sectional | Not given | 111 | Mixed cancer Patients | Receiving Radiotherapy | Dutch | $\alpha 0.84$ | |
| 28 | MFI-20 English, Smets et al. [78] Netherland and UK | Cross-sectional | Not given | 98 Dutch 116 Scottish | Mixed cancer Patients | Receiving Radiotherapy | English, Dutch | Overall 0.79-0.93 | F.A. (0.98 Dutch), 0.97 Scottish) $\alpha 0.83$ |
| 29 | MFI-20 Brazilian, Portuguese Baptista et al. [79] Brazil | Cross-sectional | Not given | 200 | Hodgkin's lymphoma | Completed treatment | Brazilian Portuguese | $\alpha 0.84$ $\alpha 0.59$ to 0.81. | |
| 30 | MFI-20 Polish, Buss et al. [55] Poland | Cross-sectional | Def 1 | 340 | Mixed cancer patients | Not specify | Polish | $\alpha 0.90$ $\alpha 0.57$ to 0.81 | |
| 31 | MFI-20 Swedish, Lundh et al. [81] Sweden | Cross-sectional | Not given | 584 | Mixed cancer Patients | Mixed | Swedish | $\alpha 0.67$ to 0.94 | |
| 32 | MFI-20 French, Fillion et al., [56] French | Cross-sectional | Not given | 604 | 277 Breast 327prostate | Mixed | French | Over all $\alpha 0.90$ $\alpha 0.68$ to 0.89 | |
| 33 | MFI-20 Hindi, Chandel et al. [80] India | Cross-sectional | Not given | 200 | Head and neck, Breast, cervical | Mixed | Hindi | Over all $\alpha 0.8$ $\alpha 0.71$ to 0.82 | |
| 34 | MFI-20 Chinese , Tian & Hong [57] China | Cross-sectional | Not given | 385 | Mixed cancer Patients | undergoing chemotherapy | Chinese | $\alpha 0.87$ $\alpha .71$ to .82 | |
| 35 | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), Stein et al., [82] USA | Longitudinal | Def 9 | 224 | Breast cancer | Mixed | English | $\alpha 0.90$ to 0.96 | $r=0.21$ - 0.82 |
| 36 | MFSI-SF, Stein et al., [83] USA | Cross-sectional | Not given | 304 | Mixed cancer Patients | undergoing chemotherapy | English | $\alpha 0.85$ to 0.960 | 10 |
| 37 | MFSI-SF Chinese Pien et al., [84] China | Cross-sectional | Def 8 | 107 | Mixed cancer Patients | Not specify | Chinese | Over all $\alpha 0.93$ $\alpha 0.83$ to 0.92 | |
| 38 | MFSI-SF Chinese Chan et al., [60] Singapore | Longitudinal | Not given | 246 | Breast cancer and lymphoma patients | undergoing Chemotherapy | Chinese Singapore | $\alpha = 0.749$ to 0.944 | $r=0.005$ - 0.185 |

| | | | | | | | | poorly correlated |
|----|---|-----------------|-----------|-----|------------------------|------------------------------|---------|---|
| 39 | Schwartz Cancer Fatigue Scale (SCFS) Schwartz,[85] USA | Cross-sectional | Def 11 | 166 | Mixed cancer Patients | Mixed | English | Over all α 0.96 α 0.82 to 0.93 |
| 40 | SCFS-R, Schwartz & Meek, [86] USA | Cross-sectional | Not given | 303 | Mixed cancer Patients | Mixed | English | Over all α 0.90 α 0.81 to 0.88 |
| 41 | SCFS-R Schwartz et al., [29] USA | Longitudinal | Not given | 226 | Mixed cancer Patients | Before chemo and after chemo | English | Over all C. α 0.85 |
| 42 | SCFS-R Chinese, Shun et al. [25] China | Cross-sectional | Def 10 | 243 | Mixed cancer Patients | Mixed | Chinese | Over all α 0.88 α 0.81 to 0.90 |
| 43 | SCFS-R Chinese Shun et al. [23] China | Longitudinal | Not given | 148 | Mixed cancer Patients | Mixed | Chinese | Over all α =0.89 |
| 44 | Fatigue Symptom Inventory (FSI), Hann et al [87] USA | Cross-sectional | Not given | 230 | Breast cancer | Mixed | English | Over all α = 0.90 |
| 45 | FSI Hann et al [88] USA | Cross-sectional | Not given | 270 | Mixed cancer patients | Not specify | English | Over all α = 0.94 |
| 46 | FSI- Chinese, Shun, et al. [25] China | Cross-sectional | Def 10 | 243 | Mixed cancer Patients | Mixed | Chinese | Over all α > 0.90 |
| 47 | FSI- Chinese, Shun, et al. [23] China | Longitudinal | Not given | 148 | Mixed cancer Patients | Mixed | Chinese | Over all α =0.70 |
| 48 | Piper Fatigue Scale-Revised (PFS-R) Piper et al. [34] USA | Cross-sectional | Not given | 382 | Breast cancer patients | Completed treatment | English | α 0.92 to 0.96 |
| 49 | PFS-R Korean, Lee [31] Korea | Cross-sectional | Not given | 122 | Breast cancer patients | Mixed | Korean | α 0.84 to 0.93 |
| 50 | PFS-R Spanish, Cantarero-Villanueva et al., [41] Spain | Cross-sectional | Not given | 111 | Breast cancer patients | Completed treatment | Spanish | Over all α 0.89 (r > 0.86) |
| 51 | PFS-R Swedish, Jakobsson et al, [27] Sweden | Cross-sectional | Not given | 196 | Mixed cancer Patients | undergoing Radiotherapy | Swedish | Over all α 0.98 α 0.93 to 0.97 |
| 52 | PFS-R Swedish, Lundgren-Nilsson, et al., [90] Sweden | Cross-sectional | Not given | 196 | Mixed cancer Patients | undergoing Radiotherapy | Swedish | Construct validity reported by Rasch analyses |

| | | | | | | | | | |
|----|--|-----------------|-----------|-----|-------------------------|---------------------|------------|---|---------------------------|
| 53 | PFS-R Dutch, Dagnelie et al. [47] Netherlands | Cross-sectional | Not given | 64 | Lung and Breast cancer | Before Radiotherapy | Dutch | Over all $\alpha > 0.90$ | |
| 54 | PFS-R Brazilian, Mota et al. [91] Brazil | Cross-sectional | Not given | 584 | Mixed cancer Patients | Mixed | Portuguese | Over all α 0.841 to 0.943 | |
| 55 | PFS-R Italian Giacalone et al. [48] Italy | Cross-sectional | Def 10 | 115 | Mixed cancer patient | Not specify | Italian | Over all $\alpha = 95$ α 0.80 to 0.94 | $r=0.77$ |
| 56 | PFS-R Italian, Annunziata et al. [30] Italy | Cross-sectional | Def 10 | 100 | Mixed cancer Patients | Not specify | Italian | Over all $\alpha = 95$ α 0.88 to 0.91 | |
| 57 | PFS-R Chinese So et al., [35] China | Cross-sectional | Def 19 | 157 | Mixed cancer Patients | Mixed | Chinese | Over all α 0.89 to 0.93 | |
| 58 | PFS-12 Reeve et al. [92] - USA | Longitudinal | Def 12 | 799 | Breast cancer survivors | Completed treatment | English | Over all $\alpha > 0.80$ α 0.87 to 0.89 | |
| 59 | Perform Questionnaire (PQ) Baró et al., [62] Spain | Cross-sectional | Def 10 | 238 | Mixed cancer patients | Mixed | Spanish | α 0.73 to 0.92 | |
| 60 | PQ, Baró et al., [65] Spain | Longitudinal | Def 13 | 437 | Mixed cancer patients | Mixed | Spanish | Over all $\alpha > 0.94$ α 0.80 to 0.90 | $r=0.83$ |
| 61 | Lee Fatigue Scale (LFS) Meek et al., [22] USA | Cross-sectional | Not given | 212 | Mixed cancer patients | Mixed | English | Over all α The variance did not support instrument constrict validity | |
| 62 | Lee Fatigue Scale (LFS) single fatigue only used Lerdal et al., [32]-USA | Longitudinal | Not given | 587 | Mixed cancer Patients | Mixed | English | Over all $\alpha = 0.89$ | Test & Retest $r=0.88$ |
| 63 | Multidimensional Assessment of Fatigue (MAF), Meek et al. [22] USA | Cross-sectional | Not given | 212 | Mixed cancer patients | Mixed | English | Over all $\alpha = 0.88$ | |
| 64 | MAF, Winstead-Fry [24] USA | Cross-sectional | Def 17 | 131 | Mixed cancer Patients | Not specify | English | Over all $\alpha = 0.89$ | |
| 65 | Cancer Fatigue Scale (CFS) Okuyama et al., [58] Japan | Longitudinal | Def 14 | 307 | Mixed cancer Patients | Not specify | Japanese | Over all $\alpha = 0.88$ 0.84 to 0.88 | $r=0.32-$ 0.67 |

| | | | | | | | | | |
|----|--|-----------------|-----------|-----|---|-------------------------|---------------------|---------------------------|-----------------------|
| 66 | CFS -J Okuyama et al., [95] Japan | Cross-sectional | Not given | 134 | Breast cancer | Completed treatment | Japanese | 0.76 to 0.89 | |
| 67 | CFS- Chinese, Shun et al., [25] China | Cross-sectional | Def 10 | 243 | Mixed cancer Patients | Mixed | Chinese | Over all $\alpha = 0.83$ | |
| 68 | CFS- Dutch, Kröz et al., [96] Germany | Longitudinal | Def 15 | 114 | 57 healthy persons 57 mixed cancer patients | Mixed | German (Dutch) | Over all $\alpha = 0.94$ | $r = 0.82$ |
| 69 | CFS- Turkish, ŞAHİN, et al., [52] Turkey | Longitudinal | Def 15 | 80 | Breast cancer | Completed treatment | Turkish | Over all $\alpha = 0.74$ | ICC 0.95 |
| 70 | CFS- Greek Charalambous, et al., [49] Greek | Cross-sectional | Def 18 | 148 | Prostate cancer | Completed treatment | Greek | Over all $\alpha = 0.916$ | $r = 0.79, p < 0.001$ |
| 71 | Hirai Cancer Fatigue Scale (HCFS) Hirai et al., [50] USA | Longitudinal | Not given | 281 | Mixed cancer Patients | Mixed | Japanese | Over all $\alpha = 0.977$ | $r = .589-0.913$ |
| 72 | Cancer-Related Fatigue Distress Scale (CRFDS) Holley [59] USA | Cross-sectional | Not given | 221 | Mixed cancer Patients | Mixed | English | Over all $\alpha = 0.943$ | $(r = 0.65)$ |
| 73 | Swedish Occupational Fatigue Inventory Åhsberg & Fürst [36] Sweden | Cross-sectional | Not given | 81 | Mixed cancer patients | undergoing radiotherapy | Swedish | $\alpha 0.73$ to 0.97 | |
| 74 | 16-item scale (WCFS), Wu & McSweeney, [42] - USA | Cross-sectional | Def 3 | 82 | Breast carcinoma | undergoing Chemo | English | Over all $\alpha > 0.95$ | |
| 75 | Wu Cancer Fatigue Scale (WCFS) R Wu et al., [51] USA | Cross-sectional | Not given | 172 | Breast cancer | undergoing Chemo | English | Over all $\alpha = 0.91$ | |
| 76 | Fatigue Functional Impact Scale (FFIS) Cella et al., [97] - USA | Cross-sectional | Not given | 401 | Mixed cancer patients | undergoing Chemo | English | Over all $\alpha = 0.90$ | |
| 77 | General Fatigue Scale (GFS), Chou et al., [98] – Taiwan | Longitudinal | Def 17 | 171 | Breast Cancer | undergoing Chemo | Chinese - Taiwanese | Over all $\alpha = 0.94$ | |

α , coefficient alpha

Table S3: Definition of fatigue in the studies:

| | Definition |
|--------|--|
| Def :1 | Fatigue is a subjective symptom and is generally thought to be related to feelings of weakness, tiredness, and lack of energy. [64] |
| Def :2 | As a multidimensional construct involving physical exhaustion, mental tiredness and a lack of energy [101] |
| Def :3 | (ICD-10), cancer-related fatigue (CRF) is defined as diminished energy, an increasing need for rest, limb heaviness, diminished ability to concentrate decreased interest in engaging in normal activities, sleep disorder, inertia, emotional liability, perceived problems with short-term memory, and postexertional malaise exceeding several hours and so on. [102] |
| Def 4 | It is defined as a subjective sensation of weakness, lack of energy, or tiredness.[61] |
| Def 5 | Being unusual or abnormal, absolutely disproportionate with respect to the amount of exercise or activity he / she has carried out, and not alleviated by resting or sleeping. [103] |
| Def 6 | A subjective sensation of feeling easily tired, weak or lacking in energy. [54] |
| Def 7 | As the subjective sensation of having reduced energy, loss of strength or becoming easily tired.[28] |
| Def 8 | Cancer-related fatigue is defined as a subjective, unusual and continuous feeling that it is cancer, it is associated or treatment- related and affects daily living activities [104] |
| Def 9 | Objectively, fatigue may be defined as a behavioral or physiologic symptom, exhibited by impaired physical, social, and vocational functioning.[82] |
| Def 10 | " A persistent, subjective sense of tiredness related to cancer or cancer treatment that interferes with usual functioning'. [105] |
| Def 11 | (NANDA) definition, which is "an overwhelming, sustained sense of exhaustion and reduced capacity for physical and mental work " [106] |
| Def 12 | The perception of unusual tiredness that varies in pattern or severity and can affect the functional ability of cancer survivors [107] |
| Def 13 | "Distressing persistent subjective sense of physical, emotional, and / or cognitive tiredness "[108] |
| Def 14 | Condition characterized by a subjective feeling of a decrease in energy, and it has both physical and psychological aspects. [109] |
| Def 15 | A persistent feeling of loss of energy and performance, fatigue, increased tiredness, lack of energy or motivation and problems with concentration. [110] |
| Def 16 | "Fatigue is a subjective state of overwhelming and sustained exhaustion and decreased capacity for physical and mental work that is not disclosed by rest [111] |
| Def 17 | As a subjective experience of tiredness, decreased energy, and decreased mental and motor skills associated with cancer therapy. [112] |
| Def 18 | "A disturbing, persistent, subjective sense of physical, emotional, and / or cognitive fatigue or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning." [10] |
| Def 19 | "An abnormal, abnormal, or excessive whole-body tiredness disproportionate to, or unrelated to, activity or exertion." Page 279 [113] |

Table S4: Unidimensional scales

| | Instrument | Number of Items | Domain | Fatigue Indication | Type of scale | Time to complete | Time period assessed |
|---|---|------------------------|----------------------|---|-----------------------|--------------------------------|-----------------------------|
| 1 | Brief Fatigue Inventory (BFI) Mendoza et al., (1999) [53] | 9 | Physical functional | 1-3 Mild 4-6 Moderate 7-10 severe | 11-Numerical (0-10) | 5 min | Past 24h |
| 2 | Modified Brief Fatigue Inventory (MBFI) Aynehchi et al., (2013) [68] | 9 | Physical functional | | 7-Numerical | Not Stated | Past 24h |
| 3 | Four-Items Fatigue Scale (FIFS), Davis et al., (2013)[38] | 4 | Physical functional | 1-3 Mild 4-6 Moderate 7-10 severe | 10-Numerical | Not Stated | Past 24h |
| 4 | Functional Assessment of Chronic Therapy-Fatigue (FACT- F) Yellen, et al. (1997) [46] | 13 | Physical Functioning | Cut-off 36 had Sensitive | 5-point Likert scale | 5-10 min | Past 7 days |
| 5 | Fatigue Assessment Scale (FAS) De Vries et al (2010) [75] | 10 | Fatigue | Higher score indicated fatigue | 5-point Likert scale | Not Stated | Present |
| 6 | Fatigue Severity Scale (FSS) Winstead-Fry P., (1998) [24] | 9 | Severity | Cut-off 5 | 7-point Likert scale | Not Stated 2-3mint Properly | Present |
| 7 | Fatigue Items Bank (FIB) Lai et al, (2005) [63] | 72 | Fatigue | Higher score indicated more fatigue | 5-point Likert scales | 20 min | Past 7 days |

Table S5: Multidimensional Scales

| | Scale | Number of items | No Domain | Domain | Fatigue Indication | Type of scale | Time to complete | Time period assessed |
|---|---|------------------------|------------------|--|---|----------------------|-------------------------|-----------------------------|
| 1 | Multidimensional Fatigue Inventory (MFI-20) Smets et al., (1995) [77] | 20 | 5 | General, physical, reduced activity, reduced motivation and mental fatigue | 4(absence fatigue) 20(maximum fatigue) | 5-point Likert scale | 5-10 min | Present |
| 2 | Multidimensional Fatigue Symptom Inventory-Short Form | 30 | 5 | General fatigue, mental, physical, emotional and Vigor | Higher score indicated | 5-point Likert scale | 5 mints | Past 7 days |

| | | | | | | | | |
|----|---|----|---|--|--|--|----------------------------|----------------------|
| | (MFSI-SF) Stein et al. (1998) [82] | | | | more fatigue | | | |
| 3 | Schwartz Cancer Fatigue Scale (SCFS) Schwartz, (1998) [85] | 28 | 4 | Physical, emotional, cognitive and temporal | Higher score indicated more fatigue | 5-point Likert scale | 5 mints | 2 to 3 days |
| 4 | Schwartz Cancer Fatigue Scale-6 (SCFS-6) Schwartz and Meek (1999)[86] | 6 | 2 | Physical and Perceptual | Higher score indicated more fatigue | 5-point Likert scale | 1 to 2 min | 2 to 3 days |
| 5 | Fatigue Symptom Inventory (FSI) Hann et al (1998) [87] | 13 | 4 | intensity, duration, daily pattern and interference | Cut-off 3 fatigue | 11-point Likert only One with 7 points | 5 min | Past 7 days, current |
| 6 | Piper Fatigue Scale-Revised (PFS-R) Piper et al. (1998) [34] | 22 | 4 | behaviour / severity, sensory, mood/ cognitive and affective meaning | 0 non 1-3 Mild 4-6 Moderate 7-10 Severe | 11-point (0-10) numeric scales | 5 min | Now |
| 7 | PFS-12 Reeve et al. (2013) [92] | 12 | 4 | behavioral, sensory, mood/ cognitive and affective | 0 non 1-3 Mild 4-6 Moderate 7-10 Severe | 11-point (0-10) numeric scales | <5 min | Now |
| 8 | Perform Questionnaire (PQ) Baró et al., (2009) [62] | 12 | 3 | Physical Limitations, Activities of Daily Living, and Beliefs and Attitudes. | Higher score indicated worse fatigue | 5-point ordinal scale | <9 min | 2 weeks |
| 9 | Lee Fatigue Scale (LFS) Meek et al., (2000) [22] | 18 | 2 | Fatigue and energy | Higher score indicated greater fatigue | 11-point (0-10) numeric scales | >2 min | Current |
| 10 | Multidimensional Assessment of Fatigue (MAF) Meek et al., (2000) [22] | 16 | 4 | Severity, distress, Interference in activity daily level, and timing | 1 (no fatigue) 50 (severe fatigue) | 0-10 | <5 min | Past 7 days |
| 11 | Cancer Fatigue Scale (CFS) Okuyama et al., (2000) [58] | 15 | 3 | Physical, affective and Cognitive | 1 (no fatigue) 60 (severe fatigue) | 5-point Likert scale | 2-3 min | Current |
| 12 | Hirai Cancer Fatigue Scale (HCFS) Hirai et al., (2015) [50] | 15 | 4 | Physical, Mental, and Cognitive fatigue | Higher score indicated greater fatigue | 5-point Likert scale | Not Given probably 2-5 min | Current |
| 13 | Cancer-Related Fatigue Distress | 23 | 5 | Physical, Social, Psychological, | Higher score | 11-point | Not | Current |

| | | | | | | | | |
|----|---|----|---|---|--|---------------------------------------|---------------------------------------|----------------|
| | Scale (CRFDS) Holley (2000) [59] | | | Cognitive and Spiritual | indicated severe fatigue | (0-10) numer ic scales | Given probl y 3-5 min | |
| 14 | Swedish Occupational Fatigue Inventory (SQFI) Åhsberg & Fürst (2001) [36] | 25 | 5 | Lack of energy, Physical exertion, Physical discomfort Lack of motivation and Sleepiness | Higher score indicated more fatigue (0-6) > 2 indicted fatigue | 7- point Likert scale | Not Given probl y 5-8 min | Current |
| 15 | 16-item scale (WCFS) Wu & McSweeney, (2004) [42] | 16 | 3 | Physical Emotional and cognitive | Higher score indicated more fatigue (15-75) | 5- point Likert scale | Not Given probl y 5 min | Past 1 day |
| 16 | Wu Cancer Fatigue Scale (WCFS) R Wu et al., (2006) [51] | 9 | 3 | Physical Emotional and cognitive | Higher score indicated more fatigue (9-45) | 5- point Likert scale | Not Given probl y 2-3 min | Past 1 day |
| 17 | Fatigue Functional Impact Scale (FFIS) Cella et al., (2008) [97] | 8 | 2 | Fatigue and functional impairment | Higher score indicated more fatigue | 10- point numer ic scales | 2-3 min | Past Month |
| 18 | General Fatigue Scale (GFS) Chou et al., (2016) [98] | 7 | 3 | Intensity, distress, disruption of daily activities | Higher score indicated more fatigue | 10- point numer ic scales | 3-5 min | Past 7 days |

References

- [1] Campos MPO, Hassan BJ, Riechelmann R, et al. Cancer-related fatigue: a practical review. *Ann. Oncol.* 2011;22:1273–1279.
- [2] de Raaf PJ, de Klerk C, Timman R, et al. Differences in Fatigue Experiences Among Patients With Advanced Cancer, Cancer Survivors, and the General Population. *J. Pain Symptom Manage.* 2012;44:823–830.
- [3] Rautalin M, Färkkilä N, Sintonen H, et al. Health-related quality of life in different states of breast cancer – comparing different instruments. *Acta Oncol.* 2018;57:622–628.
- [4] Berger AM, Mitchell SA, Jacobsen PB, et al. Screening, evaluation, and management of cancer-related fatigue: Ready for implementation to practice?: Cancer-Related Fatigue. *CA. Cancer J. Clin.* 2015;65:190–211.

- [5] Hoffman KE, McCarthy EP, Recklitis CJ, et al. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. *Arch. Intern. Med.* 2009;169:1274–1281.
- [6] Güleser GN, Taşci S, Kaplan B. The experience of symptoms and information needs of cancer patients undergoing radiotherapy. *J. Cancer Educ.* 2012;27:46–53.
- [7] Manir KS, Bhadra K, Kumar G, et al. Fatigue in breast cancer patients on adjuvant treatment: course and prevalence. *Indian J. Palliat. Care.* 2012;18:109.
- [8] Weis J. Cancer-related fatigue: prevalence, assessment and treatment strategies. *Expert Rev. Pharmacoecon. Outcomes Res.* 2011;11:441–446.
- [9] Wang XS, Woodruff JF. Cancer-related and treatment-related fatigue. *Gynecol. Oncol.* 2015;136:446–452.
- [10] Berger AM, Mooney K, Alvarez-Perez A, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Cancer-Related Fatigue, Version 1.2019 [Internet]. National Comprehensive Cancer Network; 2019 [cited 2019 Jun 4]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
- [11] Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients — an EAPC approach. *Palliat. Med.* 2008;22:13–32.
- [12] Mark W, Touloupoulou T. Psychometric Properties of “Community Assessment of Psychic Experiences”: Review and Meta-analyses. *Schizophr. Bull.* 2016;42:34–44.
- [13] Vitoratou S, Pickles A. A note on contemporary psychometrics. *J Ment Health.* 2017;26:486–488.
- [14] Huang F-F, Yang Q, Wang A, et al. Psychometric properties and performance of existing self-efficacy instruments in cancer populations: a systematic review. *Health Qual. Life Outcomes.* 2018;16:241.
- [15] Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). *Ann. Oncol.* 2008;20:17–25.
- [16] Mota DDCF, Pimenta CAM. Self-Report Instruments for Fatigue Assessment: A Systematic Review. *Res. Theory Nurs. Pract.* 2006;20:49–78.
- [17] Seyidova-Khoshknabi D, Davis MP, Walsh D. Review article: a systematic review of cancer-related fatigue measurement questionnaires. *Am. J. Hosp. Palliat. Care.* 2011;28:119–129.
- [18] Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. *J. Pain Symptom Manage.* 2009;37:107–128.
- [19] Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J. Clin. Epidemiol.* 2007;60:34–42.
- [20] Gough D, Oliver S, Thomas J. *An Introduction to Systematic Reviews.* SAGE; 2017.
- [21] Eden MM, Kunkel K. Psychometric properties of the Modified Brief Fatigue Inventory and FACIT-Fatigue in individuals with cancer of the head and neck. *Rehabil. Oncol.* 2016;34:97–103.
- [22] Meek PM, Nail LM, Barsevick A, et al. Psychometric testing of fatigue instruments for use with cancer patients. *Nurs. Res.* 2000;49:181–190.

- [23] Shun S-C, Beck SL, Pett MA, et al. Assessing Responsiveness of Cancer-Related Fatigue Instruments: Distribution-Based and Individual Anchor-Based Methods. *The Oncologist*. 2007;12:495–504.
- [24] Winstead-Fry P. Psychometric assessment of four fatigue scales with a sample of rural cancer patients. *J. Nurs. Meas.* 1998;6:111–122.
- [25] Shun S-C, Beck SL, Pett MA, et al. Psychometric Testing of Three Chinese Fatigue Instruments in Taiwan. *J. Pain Symptom Manage.* 2006;32:155–167.
- [26] Ishikawa NM, Thuler LCS, Giglio AG, et al. Reproducibility of Functional Assessment of Cancer Therapy Fatigue (FACT-F) questionnaire for cancer patients. *Appl. Cancer Res.* 2008;28:55–61.
- [27] Jakobsson S, Taft C, Östlund U, et al. Performance of the Swedish version of the Revised Piper Fatigue Scale. *Eur. J. Oncol. Nurs.* 2013;17:808–813.
- [28] Stone P, Richards MG, A'HERN R, et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. *Ann. Oncol.* 2000;11:561–567.
- [29] Schwartz AL, Meek PM, Nail LM, et al. Measurement of fatigue - Determining minimally important clinical differences. *J. Clin. Epidemiol.* 2002;55:239–244.
- [30] Annunziata MA, Muzzatti B, Mella S, et al. The Revised Piper Fatigue Scale (PFS-R) for Italian Cancer Patients: A Validation Study. *Tumori J.* 2010;96:276–281.
- [31] Lee EH. Construct validity of the revised Piper Fatigue Scale in Korean women with breast cancer. *J Korean Acad Nurs.* 1999;29:485–493.
- [32] Lerdal A, Kottorp A, Gay C, et al. A Rasch analysis of assessments of morning and evening fatigue in oncology patients using the Lee Fatigue Scale. *J. Pain Symptom Manage.* 2016;51:1002–1012.
- [33] Mystakidou K, Tsilika E, Parpa E, et al. Psychometric Properties of the Brief Fatigue Inventory in Greek Patients with Advanced Cancer. *J. Pain Symptom Manage.* 2008;36:367–373.
- [34] Piper BF, Dibble SL, Dodd MJ, et al. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. *Oncol. Nurs. Forum.* 1998;25:677–684.
- [35] So WKW, Dodgson J, Tai JWM. Fatigue and Quality of Life Among Chinese Patients With Hematologic Malignancy After Bone Marrow Transplantation. *Cancer Nurs.* 2003;26:211–219.
- [36] Åhsberg E, Fürst CJ. Dimensions of fatigue during radiotherapy--an application of the Swedish Occupational Fatigue Inventory (SOFI) on cancer patients. *Acta Oncol. Stockh. Swed.* 2001;40:37–43.
- [37] Yun YH, Wang XS, Lee JS, et al. Validation study of the Korean version of the Brief Fatigue Inventory. *J. Pain Symptom Manage.* 2005;29:165–172.
- [38] Davis MP, Khoshknabi D, Walsh D, et al. Four-Item Fatigue Screen: Replacing the Brief Fatigue Index. *Am. J. Hosp. Palliat. Med.* 2013;30:652–656.
- [39] Mendoza TR, Laudico AV, Wang XS, et al. Assessment of Fatigue in Cancer Patients and Community Dwellers: Validation Study of the Filipino Version of the Brief Fatigue Inventory. *Oncology.* 2010;79:112–117.

- [40] Yoshimura A, Kobayashi K, Fumimoto H, et al. Cross-Cultural Validation of the Japanese Functional Assessment of Cancer Therapy-Anemia (FACT-An). *J. Nippon Med. Sch.* 2004;71:314–322.
- [41] Cantarero-Villanueva I, Fernández-Lao C, Díaz-Rodríguez L, et al. The piper fatigue scale-revised: Translation and psychometric evaluation in Spanish-speaking breast cancer survivors. *Qual. Life Res.* 2014;23:271–276.
- [42] Wu H-S, McSweeney M. Assessing fatigue in persons with cancer: An instrument development and testing study. *Cancer.* 2004;101:1685–1695.
- [43] Catania G, Bell C, Ottonelli S, et al. Cancer-related fatigue in Italian cancer patients: Validation of the Italian version of the Brief Fatigue Inventory (BFI). *Support. Care Cancer.* 2013;21:413–419.
- [44] Radbruch L, Sabatowski R, Elsner F, et al. Validation of the German Version of the Brief Fatigue Inventory. *J. Pain Symptom Manage.* 2003;25:449–458.
- [45] Okuyama T, Wang XS, Akechi T, et al. Validation Study of the Japanese Version of the Brief Fatigue Inventory. *J. Pain Symptom Manage.* 2003;25:106–117.
- [46] Yellen, S., Cella, D., Webster, K., Blendowski, C. and Kaplan E. Measuring Fatigue And Other Anemia-Related Symptoms With The Functional Assessment Of Cancer Therapy (FACT) Measurement System. *J. Pain Symptom Manage.* 1997;13:63–74.
- [47] Dagnelie PC, Pijls-johannesma MCG, Pijpe A, et al. Psychometric properties of the revised Piper Fatigue Scale in Dutch cancer patients were satisfactory. 2006;59:642–649.
- [48] Giacalone A, Polesel J, De Paoli A, et al. Assessing cancer-related fatigue: the psychometric properties of the Revised Piper Fatigue Scale in Italian cancer inpatients. *Support. Care Cancer.* 2010;18:1191–1197.
- [49] Charalambous A, Kaite C, Constantinou M, et al. Translation and validation of the Cancer-Related Fatigue Scale in Greek in a sample of patients with advanced prostate cancer. *BMJ Open.* 2016;6:e011798.
- [50] Hirai K, Kanda K, Takagai J, et al. Development of the Hirai Cancer Fatigue Scale: Testing its reliability and validity. *Eur. J. Oncol. Nurs.* 2015;19:427–432.
- [51] Wu H-S, Wyrwich KW, McSweeney M. Assessing Fatigue in Persons with Cancer: Further Validation of the Wu Cancer Fatigue Scale. *J. Pain Symptom Manage.* 2006;32:255–265.
- [52] Şahin S, Huri M, Aran OT, et al. Cross-cultural adaptation, reliability, and validity of the Turkish version of the Cancer Fatigue Scale in patients with breast cancer. *Turk. J. Med. Sci.* 2018;48:124–130.
- [53] Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients. *Cancer.* 1999;85:1186–1196.
- [54] Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. *Br. J. Cancer.* 1999;79:1479–1486.
- [55] Buss T, Kruk A, Wiśniewski P, et al. Psychometric properties of the polish version of the multidimensional fatigue inventory-20 in cancer patients. *J. Pain Symptom Manage.* 2014;48:730–737.

- [56] Fillion L, Gélinas C, Simard S, et al. Validation evidence for the French Canadian adaptation of the Multidimensional Fatigue Inventory as a measure of cancer-related fatigue. *Cancer Nurs.* 2003;26:143–154.
- [57] Tian J, Hong JS. Validation of the Chinese version of Multidimensional Fatigue Inventory-20 in Chinese patients with cancer. *Support. Care Cancer.* 2012;20:2379–2383.
- [58] Okuyama T, Akechi T, Kugaya A, et al. Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. *J. Pain Symptom Manage.* 2000;19:5–14.
- [59] Holley SK. Evaluating patient distress from cancer-related fatigue: an instrument development study. *Oncol. Nurs. Forum.* 2000;27:1425–1431.
- [60] Chan A, Lew C, Wang XJ, et al. Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. *Health Qual. Life Outcomes* [Internet]. 2018 [cited 2018 May 3];16. Available from: <https://hql.o.biomedcentral.com/articles/10.1186/s12955-018-0846-6>.
- [61] Dapueto JJ, del Carmen Abreu M, Francolino C, et al. Psychometric Assessment of the MSAS-SF and the FACIT-Fatigue Scale in Spanish-Speaking Patients With Cancer in Uruguay. *J. Pain Symptom Manage.* 2014;47:936–945.
- [62] Baró E, Carulla J, Cassinello J, et al. Development of a New Questionnaire to Assess Patient Perceptions of Cancer-Related Fatigue : Item Generation and Item Reduction. *Value Health.* 2009;12:130–138.
- [63] Lai J, Cella D, Dineen K, et al. An item bank was created to improve the measurement of cancer-related fatigue. *J. Clin. Epidemiol.* 2005;58:190–197.
- [64] Lin CC, Chang AP, Chen ML, et al. Validation of the Taiwanese Version of the Brief Fatigue Inventory. *J. Pain Symptom Manage.* 2006;32:52–59.
- [65] Baró E, Carulla J, Cassinello J, et al. Psychometric properties of the Perform Questionnaire: A brief scale for assessing patient perceptions of fatigue in cancer. *Support. Care Cancer.* 2011;19:657–666.
- [66] Wang XS, Hao X-S, Wang Y, et al. Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). *J. Pain Symptom Manage.* 2004;27:322–332.
- [67] Paramita N, Nusdwinuringtyas N, Annisa Nuhonni S, et al. Validity and Reliability of Brief Fatigue Inventory (BFI)-Indonesian Version in Cancer Patients. *J. Pain Symptom Manage.* 2016;
- [68] Aynehchi BB, Obourn C, Sundaram K, et al. Validation of the Modified Brief Fatigue Inventory in Head and Neck Cancer Patients. *Otolaryngol.-Head Neck Surg.* 2013;148:69–74.
- [69] FACIT. FACIT Trans Home [Internet]. 2018 [cited 2018 May 14]. Available from: <http://www.facit.org/TransHome>.
- [70] Van Belle S, Paridaens R, Evers G, et al. Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. *Support. Care Cancer.* 2005;13:246–254.

- [71] Meysami A, Yari H, Haghghat S, et al. The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue Subscale): Validity and Reliability of the Iranian Version. *Oncol. Res. Treat.* 2017;40:789–793.
- [72] Ishikawa NM, Thuler LCS, Giglio AG, et al. Validation of the Portuguese version of Functional Assessment of Cancer Therapy-Fatigue (FACT-F) in Brazilian cancer patients. *Support. Care Cancer.* 2010;18:481–490.
- [73] Michielsen HJ, De Vries J, Van Heck GL, et al. Examination of the Dimensionality of Fatigue: The Construction of the Fatigue Assessment Scale (FAS). *Eur. J. Psychol. Assess.* 2004;20:39.
- [74] Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. *J. Psychosom. Res.* 2003;54:345–352.
- [75] De Vries J, Van der Steeg AF, Roukema JA. Psychometric properties of the Fatigue Assessment Scale (FAS) in women with breast problems. *Int. J. Clin. Health Psychol.* 2010;10:125–139.
- [76] Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch. Neurol.* 1989;46:1121–1123.
- [77] Smets EMA, Garssen B, Bonke B, et al. The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. *J. Psychosom. Res.* 1995;39:315–325.
- [78] Smets E, Garssen B, Cull A, et al. Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. *Br. J. Cancer.* 1996;73:241–245.
- [79] Baptista RLR, Biasoli I, Scheliga A, et al. Psychometric properties of the multidimensional fatigue inventory in Brazilian Hodgkin's lymphoma survivors. *J. Pain Symptom Manage.* 2012;44:908–915.
- [80] Chandel P, Sultan A, Khan KA, et al. Validation of the Hindi version of the Multidimensional Fatigue Inventory-20 (MFI-20) in Indian cancer patients. *Support. Care Cancer.* 2015;23:2957–2964.
- [81] Hagelin CL, Wengström Y, Runesdotter S, et al. The psychometric properties of the Swedish Multidimensional Fatigue Inventory MFI-20 in four different populations. *Acta Oncol. Stockh. Swed.* 2007;46:97–104.
- [82] Stein KD, Martin SC, Hann DM, et al. A Multidimensional Measure of Fatigue for Use with Cancer Patients. *Cancer Pract.* 1998;6:143–152.
- [83] Stein KD, Jacobsen PB, Blanchard CM, et al. Further validation of the multidimensional fatigue symptom inventory-short form. *J. Pain Symptom Manage.* 2004;27:14–23.
- [84] Pien LC, Chu H, Chen WC, et al. Reliability and validity of a Chinese version of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF-C). *J. Clin. Nurs.* 2011;20:2224–2232.
- [85] Schwartz AL. The Schwartz Cancer Fatigue Scale : Testing reliability and validity. *Oncol. Nurs. Forum.* 1998;25:711–717.
- [86] Schwartz A, Meek P. Additional construct validity of the Schwartz Cancer Fatigue Scale. *J. Nurs. Meas.* 1999;7:35–45.
- [87] Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. *Qual. Life Res.* 1998;7:301–310.

- [88] Hann DM, Denniston MM, Baker F. Measurement of fatigue in cancer patients: Further validation of the Fatigue Symptom Inventory. *Qual. Life Res.* 2000;9:847–854.
- [89] Piper BF. Piper fatigue scale available for clinical testing. *Oncol. Nurs. Forum.* 1990;17:661–662.
- [90] Lundgren-Nilsson Å, Dencker A, Jakobsson S, et al. Construct Validity of the Swedish Version of the Revised Piper Fatigue Scale in an Oncology Sample—A Rasch Analysis. *Value Health.* 2014;17:360–363.
- [91] Mota DDCF, Pimenta CAM, Piper BF. Fatigue in Brazilian cancer patients, caregivers, and nursing students: A psychometric validation study of the Piper Fatigue Scale-Revised. *Support. Care Cancer.* 2009;17:645–652.
- [92] Reeve BB, Stover AM, Alfano CM, et al. The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. *Breast Cancer Res. Treat.* 2012;136:9–20.
- [93] Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. *Psychiatry Res.* 1991;36:291–298.
- [94] Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. *J. Rheumatol.* 1995;22:639–643.
- [95] Okuyama T, Akechi T, Kugaya A, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. *Support. Care Cancer.* 2000;8:215–222.
- [96] Kröz M, Zerm R, Reif M, et al. Validation of the German version of the Cancer Fatigue Scale (CFS-D): Original article. *Eur. J. Cancer Care (Engl.).* 2008;17:33–41.
- [97] Cella D, Viswanathan HN, Hays RD, et al. Development of a Fatigue and Functional Impact Scale in anemic cancer patients receiving chemotherapy. *Cancer.* 2008;113:1480–1488.
- [98] Chou H-L, Hsieh P-C, Yao C-T, et al. Validity and Reliability of the Taiwanese Version of the General Fatigue Scale in Cancer Patients. *Cancer Nurs.* 2016;39:495.
- [99] Agasi-Idenburg C, Velthuis M, Wittink H. Quality criteria and user-friendliness in self-reported questionnaires on cancer-related fatigue: a review. *J. Clin. Epidemiol.* 2010;63:705–711.
- [100] Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. *Qual. Life Res.* 2018;27:1159–1170.
- [101] Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. *Support. Care Cancer.* 1996;4:82–96.
- [102] Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. *J. Clin. Oncol.* 2001;19:3385–3391.
- [103] Gall H. The basis of cancer fatigue: where does it come from? *Eur. J. Cancer Care (Engl.).* 1996;5:31–34.
- [104] Franklin DJ, Packel L. Cancer-Related Fatigue. *Arch. Phys. Med. Rehabil.* 2006;87:91–93.
- [105] Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. *Oncol. Williston Park N.* 2000;14:151–161.

- [106] North American Nursing Diagnosis Association. Nanda nursing diagnoses: definitions and classification 1997-1998. Philadelphia, Penn.: North American Nursing Diagnosis Association; 1996.
- [107] Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. *J. Natl. Compr. Canc. Netw.* 2010;8:958–966.
- [108] Piper BF, Borneman T, Sun VC, et al. Cancer-related fatigue: role of oncology nurses in translating National Comprehensive Cancer Network assessment guidelines into practice., *Assessment of Cancer-Related Fatigue: Role of the Oncology Nurse in Translating NCCN Assessment Guidelines into Practice.* *Clin. J. Oncol. Nurs.* 2008;12, 12:37, 37–47.
- [109] Pickard-Holley S. Fatigue in cancer patients: A descriptive study. *Cancer Nurs.* 1991;14:13–19.
- [110] National Comprehensive Cancer. Cancer-related fatigue. *Clinical practice guidelines in oncology.* *J. Natl. Compr. Canc. Netw.* 2003;1:308.
- [111] Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. *Oncol. Williston Park N.* 1998;12:369–377.
- [112] Winningham ML, Nail LM, Burke MB, et al. Fatigue and the cancer experience: the state of the knowledge. *Oncol. Nurs. Forum.* 1994;21:23–36.
- [113] Piper B. Fatigue. In: Carrieri-Kohlman V, Lindsey A, West C, editors. *Pathophysiol. Phenom. Nurs. Hum. Responses Illn.* 2e. 2 edition. Philadelphia: Saunders; 1993. p. 279–302.